Summary of evidence and Expert Committee recommendations
Cisplatin was originally added to the EML in 1984 and to the EMLc in 2007. In 2009, cisplatin was replaced by carboplatin with a square box for treatment of advanced ovarian cancer.
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, cisplatin was added to the complementary list of the EML and EMLc for use in treatment protocols for ovarian germ cell tumours. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for ovarian germ cell tumours is attached.